Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.

导出 OA

翻译打印收藏纠错

第一作者： Arkadiusz Z,Dudek

第一单位： Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.

作者： Arkadiusz Z,Dudek ^[1] ; Li C,Liu ^[2] ; Shilpa,Gupta ^[3] ; Theodore F,Logan ^[4] ; Eric A,Singer ^[5] ; Monika,Joshi ^[6] ; Yousef N,Zakharia ^[7] ; Joshua M,Lang ^[8] ; James K,Schwarz ^[9] ; Anas,Al-Janadi ^[10] ; Ajjai S,Alva ^[11]

作者单位： Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL. ^[1] Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL. ^[2] Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN. ^[3] Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN. ^[4] Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. ^[5] Penn State Cancer Institute, Pennsylvania State University, State College, PA. ^[6] University of Iowa Hospitals and Clinics, University of Iowa, Iowa City, IA. ^[7] Carbone Cancer Center, University of Wisconsin, Madison, WI. ^[8] Fred & Pamela Buffett Cancer Center, Omaha, NE. ^[9] MSU Breslin Cancer Center, Michigan State University, Lansing, MI. ^[10] Rogel Cancer Center, University of Michigan, Ann Arbor, MI. ^[11]